Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454481 | 1.00 | LCK (0.56) | LCKMAPTCASP3SENP8SENP7 | |
| SCHEMBL23183609 | 0.86 | DYRK1A (0.67) | LCKMAPTDYRK1A | |
| SCHEMBL1284899 | 0.86 | MAPT (0.76) | LCKMAPTKDM4EMEN1NPC1 | |
| SCHEMBL1284898 | 0.85 | MAPT (0.55) | LCKMAPTDYRK1A | |
| SCHEMBL3283781 | 0.85 | MAPT (0.55) | LCKMAPTDYRK1A | |
| SCHEMBL26528522 | 0.84 | MAPT (0.52) | LCKMAPTDYRK1AKDM4EMEN1 | |
| SCHEMBL3224565 | 0.84 | MAPT (0.52) | LCKMAPTDYRK1AMEN1NPC1 | |
| SCHEMBL29582204 | 0.84 | MAPT (0.52) | LCKMAPTDYRK1AKDM4EMEN1 | |
| SCHEMBL3053547 | 0.84 | DYRK1A (0.70) | LCKMAPTDYRK1AKDM4EMEN1 | |
| SCHEMBL3212819 | 0.84 | MAPT (0.54) | LCKMAPTDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676480-A1 | INHIBITORS OF DNA POLYMERASE THETA | Breakpoint Therapeutics GmbH (DE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4626888-A1 | COMPOUNDS | Redx Pharma Limited (GB) | 2025-10-08 | — | — | EP | disclosed |
| US-12162895-B2 | DNA polymerase theta inhibitor for treatment of cancer | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-12-10 | — | — | US | disclosed |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-11-19 | — | — | US | disclosed |
| US-20240336628-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-10 | — | — | US | disclosed |
| US-20240327431-A1 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-20240327430-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| WO-2024189493-A1 | INHIBITORS OF DNA POLYMERASE THETA | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024115890-A1 | COMPOUNDS | REDX PHARMA PLC (GB) | 2024-06-06 | — | — | WO | disclosed |
| CN-117651700-A | 2-aminobenzothiazole compounds and methods of use | 安进公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117083279-A | Oxazepine compounds and their use in the treatment of cancer | 基因泰克公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-19 | — | — | US | disclosed |
| CN-116368130-A | Heterocyclic compounds and their use | 金橘生物科技公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023274383-A1 | KRAS G12D INHIBITOR AND USE THEREOF | 上海迪诺医药科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| CN-115135636-A | Quinoxalinone derivatives as irreversible inhibitors of KRAS G12C mutant proteins | 北京泰德制药股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022047260-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021219090-A1 | QUINOXALINE DIONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN | 北京泰德制药股份有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162895-B2 | DNA polymerase theta inhibitor for treatment of cancer | POLQ, POLB, POLH | LCK 2285/4885MAPT 1209/4885CASP3 4430/4885 |
| US-20240327430-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | POLQ, POLK, POLB | LCK 1110/4885MAPT 1489/4885CASP3 3804/4885 |
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, KRAS, HRAS | LCK 142/4885MAPT 3074/4885CASP3 1814/4885 |
| US-20240336628-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | POLQ, POLK, POLB | LCK 1110/4885MAPT 1489/4885CASP3 3804/4885 |
| US-20240327431-A1 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | POLQ, POLB, POLH | LCK 2285/4885MAPT 1209/4885CASP3 4430/4885 |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | POLQ, POLK, POLB | LCK 1605/4885MAPT 1441/4885CASP3 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.